SYNCHRONY

The Phase 3 SYNCHRONY clinical trial program consists of three randomized, placebo-controlled trials:

  • SYNCHRONY Histology, which is evaluating the efficacy and safety of EFX in patients with biopsy-confirmed pre-cirrhotic (F2-F3) MASH;
  • SYNCHRONY Real-World, which is assessing the safety and tolerability of EFX in patients with noninvasively diagnosed MASH or metabolic dysfunction-associated steatotic liver disease (MASLD) (F1-F4);
  • SYNCHRONY Outcomes, which is evaluating EFX for the treatment of compensated cirrhosis (F4) due to MASH.
Read more about study details at ClinicalTrials.gov: SYNCHRONY Histology, SYNCHRONY Real-World, and SYNCHRONY Outcomes. Learn more about enrolling in the SYNCHRONY Histology clinical trial.

Pipeline

We are advancing Efruxifermin (EFX) for the treatment of NASH.

View Our Pipeline